DIPG Panel Discussion, page-14

GD2-CAR T-Cell Therapy for H3K27M-Mutated Diffuse Midline Gliomas
Written by Patrick Y. Wen MD
Despite the toxicities and the variable results, these preliminary cases suggest that GD2 CAR T-cell therapy holds significant promise for H3K27M+ DIPG/DMG, and additional results from this trial are eagerly awaited.

https://www.practiceupdate.com/content/2022-top-story-in-brain-cancer-gd2-car-t-cell-therapy-for-h3k27m-mutated-diffuse-midline-gliomas/143617/61/12/3

Matt Dun's Lab would be coordinating the development of a less toxic GD2 CAR T-cell therapy for H3K27M+ DIPG/DMG, in combination with ONC201 and paxalisib (PNOC study).

Regards.